Ahmet Sezer

2.2k total citations
48 papers, 402 citations indexed

About

Ahmet Sezer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ahmet Sezer has authored 48 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Ahmet Sezer's work include Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (15 papers) and Inflammatory Biomarkers in Disease Prognosis (6 papers). Ahmet Sezer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (15 papers) and Inflammatory Biomarkers in Disease Prognosis (6 papers). Ahmet Sezer collaborates with scholars based in Türkiye, United States and Ukraine. Ahmet Sezer's co-authors include Özgür Özyılkan, Ali Ayberk Beşen, Hüseyin Mertsoylu, Fatih Köse, Ahmet Taner Sümbül, Uğur Selek, Erkan Topkan, Ahmet Küçük, Yurday Özdemir and Umut Dişel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ahmet Sezer

43 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ahmet Sezer Türkiye 11 235 168 77 44 43 48 402
Birsen Yücel Türkiye 11 205 0.9× 123 0.7× 64 0.8× 57 1.3× 48 1.1× 53 362
Sernaz Uzunoğlu Türkiye 12 246 1.0× 153 0.9× 144 1.9× 52 1.2× 69 1.6× 61 503
Gareth Rees United Kingdom 10 209 0.9× 172 1.0× 81 1.1× 37 0.8× 19 0.4× 21 403
Maurizio Leoni Italy 11 168 0.7× 95 0.6× 43 0.6× 44 1.0× 35 0.8× 21 290
R. Blanco Spain 9 282 1.2× 227 1.4× 68 0.9× 9 0.2× 44 1.0× 12 511
Raj Singh United States 11 177 0.8× 266 1.6× 111 1.4× 23 0.5× 31 0.7× 50 485
Droz Jp France 8 187 0.8× 183 1.1× 172 2.2× 69 1.6× 58 1.3× 32 420
Burton Needles United States 10 330 1.4× 104 0.6× 151 2.0× 34 0.8× 48 1.1× 17 544
Carla Codecà Italy 10 169 0.7× 112 0.7× 82 1.1× 99 2.3× 33 0.8× 19 364
Ping‐Tsung Chen Taiwan 14 201 0.9× 126 0.8× 120 1.6× 54 1.2× 59 1.4× 35 436

Countries citing papers authored by Ahmet Sezer

Since Specialization
Citations

This map shows the geographic impact of Ahmet Sezer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmet Sezer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmet Sezer more than expected).

Fields of papers citing papers by Ahmet Sezer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmet Sezer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmet Sezer. The network helps show where Ahmet Sezer may publish in the future.

Co-authorship network of co-authors of Ahmet Sezer

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmet Sezer. A scholar is included among the top collaborators of Ahmet Sezer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmet Sezer. Ahmet Sezer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sümbül, Ahmet Taner, et al.. (2023). Pertuzumab-mediated Cardiotoxicity: A Single Center Study.. SHILAP Revista de lepidopterología.
2.
Murray, Joseph C., Valsamo Anagnostou, Julie R. Brahmer, et al.. (2023). Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.. Journal of Clinical Oncology. 41(16_suppl). 9028–9028. 1 indexed citations
3.
4.
Gandara, David R., Ahmet Sezer, Mahmut Gümüş, et al.. (2023). MA05.11 Predictive Utility of Patient-Reported Outcomes for Survival in 1st-Line Treated Patients with a NSCLC in EMPOWER-Lung 1 and 3. Journal of Thoracic Oncology. 18(11). S117–S117.
5.
6.
Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross‐Goupil, et al.. (2021). 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. Annals of Oncology. 32. S651–S652. 7 indexed citations
7.
Topkan, Erkan, Hüseyin Mertsoylu, Ahmet Küçük, et al.. (2020). Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. Gastroenterology Research and Practice. 2020. 1–8. 28 indexed citations
8.
Topkan, Erkan, Yurday Özdemir, Ahmet Küçük, et al.. (2020). Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy. Journal of Oncology. 2020. 1–10. 7 indexed citations
9.
10.
11.
Sezer, Ahmet, Miranda Gogishvili, Dmitry Bentsion, et al.. (2019). P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%. Journal of Thoracic Oncology. 14(10). S638–S638. 1 indexed citations
12.
13.
Sümbül, Ahmet Taner, et al.. (2014). Low serum levels of vitamin D in metastatic cancer patients: a case–control study. Medical Oncology. 31(3). 861–861. 6 indexed citations
14.
Mertsoylu, Hüseyin, Ali Ayberk Beşen, Ahmet Sezer, et al.. (2014). Primary Extranodal Non-Hodgkin's Lymphoma: Clinicopathological Features, Survival and Treatment Outcome in Two Cancer Centers of Southern Turkey. Asian Pacific Journal of Cancer Prevention. 15(17). 7207–7211. 7 indexed citations
15.
Köse, Fatih, Tarkan Ergün, Ahmet Sezer, et al.. (2014). Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases. Molecular and Clinical Oncology. 3(2). 400–402. 4 indexed citations
16.
Dişel, Umut, Ali Ayberk Beşen, Hüseyin Mertsoylu, et al.. (2012). Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study. Medical Oncology. 29(5). 3608–3613. 8 indexed citations
17.
Köse, Fatih, et al.. (2012). Kaposis Sarcoma following Chronic Lymphocytic Leukemia: A Rare Entity. Case Reports in Oncology. 5(2). 271–274. 4 indexed citations
18.
Dişel, Umut, Serdar Öztuzcu, Ali Ayberk Beşen, et al.. (2010). Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer. 71(1). 109–112. 26 indexed citations
19.
Köse, Fatih, Hüseyin Mertsoylu, Ahmet Sezer, et al.. (2009). Primary Renal Lymphoma: Report of Four Cases. Oncology Research and Treatment. 32(4). 200–202. 17 indexed citations
20.
Köse, Fatih, et al.. (2008). Colon Adenocarcinoma and Solitary Tibia Metastasis: Rare Entity. Journal of Gastrointestinal Cancer. 39(1-4). 146–148. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Birsen Yücel Breakdown of academic impact, for papers by Sernaz Uzunoğlu Breakdown of academic impact, for papers by Gareth Rees Breakdown of academic impact, for papers by Maurizio Leoni Breakdown of academic impact, for papers by R. Blanco Breakdown of academic impact, for papers by Raj Singh Breakdown of academic impact, for papers by Droz Jp Breakdown of academic impact, for papers by Burton Needles Breakdown of academic impact, for papers by Carla Codecà Breakdown of academic impact, for papers by Ping‐Tsung Chen
Rankless by CCL
2026